Traditional Chinese medicine for the treatment of pulmonary fibrosis: A protocol for systematic review and meta-analysis of overview
| Autor: | Liying Lu, Wenna Yang, Jinghui Zheng, Xuan Chen, Yixuan Kong, Xiangmei Xu, Jie Wang, Li-Juan Li |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty curative effect Pulmonary Fibrosis Pneumonia Viral MEDLINE Traditional Chinese medicine Cochrane Library Pulmonary function testing 03 medical and health sciences Idiopathic pulmonary fibrosis Betacoronavirus 0302 clinical medicine Meta-Analysis as Topic Pulmonary fibrosis Study Protocol Systematic Review Medicine Traditional Chinese Medicine Humans 030212 general & internal medicine Medicine Chinese Traditional Intensive care medicine Pandemics business.industry SARS-CoV-2 COVID-19 General Medicine medicine.disease COVID-19 Drug Treatment Systematic review Treatment Outcome re-evaluation of systematic evaluation Research Design 030220 oncology & carcinogenesis Meta-analysis Female business Coronavirus Infections Research Article Drugs Chinese Herbal Systematic Reviews as Topic |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 |
| Popis: | Background: Since December 2019, there have been many cases of viral pneumonia of unknown causes in Wuhan City, Hubei Province. During the period of novel coronavirus, according to the observation of limited autopsy and biopsy pathological results, pulmonary interstitial fibrosis appeared in some pathological changes of lung. Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial pneumonia with unknown etiology and pathological changes limited to the lung. At present, there is still a lack of reevaluation of systematic evaluation of traditional Chinese medicine treatment IPF. Therefore, a systematic re-evaluation of the systematic evaluation of traditional Chinese medicine in the treatment of pulmonary fibrosis may help to understand the effective treatment scheme of traditional Chinese medicine in the treatment of pulmonary fibrosis and provide more reliable evidence for the first-line clinicians to treat novel coronavirus. Methods: We will search 3 foreign electronic databases (Cochrane Library, Embase, PubMed) and 4 Chinese electronic databases (China National Knowledge Infrastructure [CNKI], WangFang Database, Chinese Biomedical Literature Database [CBM], and Chinese Scientific Journal Database [VIP]) to collect potential systematic reviews from their inceptions to February 2020. The language of publication is limited to Chinese or English. We will consider SRs and meta-analysis of Traditional Chinese Medicine for the Treatment of pulmonary fibrosis. Two reviewers will identify relevant studies, and then assess the methodological quality by assessment of multiple systematic reviews-2 tool. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) report checklist to assess the quality of reports included in the study. In order to better evaluate the systematic evaluation included in this research, risk of bias in systematic review tool is included in this research to evaluate the methodological quality. The quality of evidence of the included systematic reviews was assessed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. The Primary outcomes include: Clinical total effective rate, curative effect of TCM symptoms, pulmonary function and blood gas analysis. Results: The results of this study will be published in a peer-reviewed journal. Conclusions: We expect to obtain reliable evidence from systematic analysis of traditional Chinese medicine treatment of pulmonary fibrosis in an available and useful document. Registration number: INPLASY202060029 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|